Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/13—Amines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/13—Amines
  • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/445—Non condensed piperidines, e.g. piperocaine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
  • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
  • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
  • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
  • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings

Definitions

• This invention relates to 2-amino-2,3-dihydro-1H-phenalene ring compounds, some of which are new compounds, which have been found to have anti-psychotic drug activity. More particularly, this invention provides a group of 2-amino-2,3-dihydro-1H-phenalene compounds, either unsubstituted in the phenalene ring system, or substituted on the 4-, 5- or 6-position with a substituent defined hereinbelow, which have been found to have useful ranges of anti-psychotic activity.
• neuroleptic drugs are known to exhibit, to a lesser or higher degree, extrapyramidal system side effects, such as catalepsy, which side effects Central Nervous System (CNS) drug researchers would prefer to avoid.
• CNS Central Nervous System
• the 2-amino-2,3-dihydro-1H-phenalene compounds are believed to have excellent antipsychotic activity as predicted by some standard laboratory animal tests, and it is hoped that the compounds hereof will have no, or at least reduced, CNS extrapyramidal side effects in their use as antipsychotic drugs.
• this invention provides a method or process for treating psychotic symptoms in human and valuable warm-blooded animal patients which comprises administering to said patient a 2 -amino-2,3-dihydro-1H-phenalene compound of formula I herebelow, in an amount sufficient to relieve the symptoms of psychotic behavior in said patient.
• This invention also provides a defined group of new compounds per se, of formula I herebelow, which are useful in appropriate pharmaceutical dosage unit forms, as drugs for treating patients suffer ing from psychotic symptoms, to relieve those symptoms of psychosis in said patient.
• the compounds of this invention hopefully will show the advantage over neuroleptic type drugs of having little or no extrapyramidal CNS side effects.
• the lead compound of this group of 2-amino-2,3-dihydro ⁇ 1H-phenalenes being tested as an antipsychotic drug is 2-(N,N-di-n ⁇ propylamino)-5-hydroxy-2,3-dihydro-1H-phenalene, in its racemic ( ⁇ ) form or as its separated stereo dextro (+) and levo (-) isomeric forms. Advanced testing is being suggested with the dextro (+) isomer of this compound.
• this invention provides a new method or process and some new compounds for treating psychotic patients to eliminate or reduce the symptoms of psychosis, which comprises administering to such a psychotic patient, in appropriate dosage unit form, a 2-amino-2,3-dihydro-1H-phenalene compound of formula I (See the structural Formula sheets) where R 1 and R 2 are independently selected from the group consisting of hydrogen, C 1 to C 4 -alkyl, C 2 to C 4 -alkenyl, C 3 to C 6 -cycloalkyl, or
• R 1 and R 2 are taken together with the nitrogen to which they are bonded to complete a nitrogen containing ring selected from the group consisting of 1-azetidinyl, 1-pyrrolidinyl, 1-piperidinyl and 4-morpholinyl;
• R 3 is selected from the group consisting of hydrogen, C 1 to C 4 -alkyl, C 1 to C 4 -alkyloxy, -trifluoromethyl,
• R 4 is phenyl, or phenyl substituted with 1 to 3 substituents selected from the group consisting of G 1 to C 4 -alkyl, C 1 to C 4 -alkyloxy,
• R 5 is hydrogen or methyl; n is 0 to 2; m is 0 to 2 in its racemic or optically active form, or a pharmaceutically acceptable acid addition salt thereof.
• C 1 to C 2 -alkyl means the methyl and ethyl groups.
• C 1 to C 3 -alkyl further includes n-propyl and isopropyl groups.
• C 1 to C 4 -alkyl further includes the butyl group in its various isomeric forms.
• C 1 to C 2 -alkyloxy means methyloxy and ethyloxy.
• C 1 to C 2 -alkyloxycarbonyl means methoxycarbonyl (CH 3 OC(O)-) or ethyloxycarbonyl C 2 H 5 -OC(O)-
• C 1 to C 5 -alkanoyloxy means acetyloxy, propionyloxy, butanoyloxy or pentanoyloxy, e.g., CH 3 COO- is acetyloxy.
• acid addition salts of these compounds include the hydrohalide salts such as the hydrochloride, hydrobromide, hydrofluoride and hydroiodide, the sulfate and bisulfate, various phosphorus acid salts, the methanesulfonate, the p-toluenesulfonate, the benzoate, the acetate, and other alkanoic acid salts, as well as the salts of various dicarboxylic and tricarboxylic acids such as maleic, succinic, fumaric, malic, oxalic, itaconic acids, and the like.
• oxalic acid may be preferred for extracting the active amino or azetidine derivative from its reaction mixture, while other acids, e.g., succinic, maleic or p-toluenesulfonic may be preferred when the resulting amine or azetidine salt is to be formulated into pharmaceutically useful form.
• succinic, maleic or p-toluenesulfonic may be preferred when the resulting amine or azetidine salt is to be formulated into pharmaceutically useful form.
• the formula I compound and its acid addition salt in their crystalline state may sometimes be isolated as solvates, i.e., with a discrete quantity of water or other solvent such as ethyl acetate, ethanol, and the like, associated physically and thus removable without effective alteration of the active chemical drug entity per se.
• the formula I compounds of this invention can be resolved into their respective d- and 1-optical isomers by methods known in the art.
• the optical resolution can be done by at least two different routes.
• the resolving agents by either route are any of the known resolving agents such as optically active dibenzoyltartaric acid, camphorsulfonic acid, bis-o-toluoyltartaric acid, tartaric acid, and diacetyl tartaric acid which are commercially available and which are commonly used for resolution of amines (bases), as for example in Organic Synthesis, Coll. Vol. V., p. 932 (1973), resolution of R- (+) and S- (-) - ⁇ -phenylethylamine with (-)-tartaric acid.
• one of the formula I 2- (N.N-di-n-propyl)-5-methyl-2,3-dihydro-1H-phenalen-2-ylamine, or other amine compounds can be converted into its optically active diastereomeric salts by reaction with an optically active acid - examples mentioned abovein a manner standard in the isomer resolution art.
• These diastereomeric salts can then be separated by conventional means such as differential crystallization. Diastereomeric salts have different crystallization properties, which are taken advantage of in this separation.
• an amine-containing precursor to a formula I compound can first be resolved as above and then converted to an optically active form of a formula I compound.
• the new compounds of this invention are compounds of formula I, where
• R 1 and R 2 are independently selected from the group consisting of hydrogen, C 1 to C 4 -alkyl, C 2 to C 4 -alkenyl, C 3 to C 6 -cycloalkyl, or
• R 1 and R 2 are taken together with the nitrogen to which they are bonded to complete a nitrogen containing ring selected from the group consisting of 1-azetidinyl, 1-pyrrolidinyl, 1-piperidinyl and 4-morpholinyl;
• R 3 is selected from the group consisting of hydrogen, C 1 to C 4 -alkyl, C 1 to C 4 -alkyloxy,
• R 4 is phenyl, or phenyl substituted with 1 to 3 substituents selected from the group consisting of C 1 to C 4 -alkyl, C 1 to C 4 -alkyloxy, C 1 to C 4 -alkyl-S-, fluorine, chlorine and bromine,
• R 5 is hydrogen or methyl; n is 0 to 2; m is 0 to 2; or an acid addition salt thereof, except 2,3-dihydro-N-methyl-1H-phenalen-2-amine, 2,3-dihydro-N-(dimethyl)-1H-phenalen-2-amine,
• a preferred group of these 2-amino-2,3-dihydro-1H-phenalene compounds for this antipsychotic drug use are compounds of formula III (See Structural Formula Sheet) where R 3 is hydrogen or is a substituent in the 5- position of the ring system thereof, R 1 and R 2 are each hydrogen or C 1 to C 4 -alkyl, and R 3 is C 1 to C 4 -alkyloxy or hydroxy, or a pharmaceutically acceptable salt thereof. Examples of such compounds include :
• alkyloxy group R 3 in the 5-position can also be ethyloxy, n-propyloxy, isopropyloxy, n-butyloxy, isobutyloxy or tert-butoxy.
• alkyloxy group R 3 in the 5-position can also be ethyloxy, n-propyloxy, isopropyloxy, n-butyloxy, isobutyloxy or tert-butoxy.
• a few examples of such compounds include:
• U-64,273A is potent in reversing the effect of d-amphetamine on nigral DA neuronal firing.
• Standard antipsychotic agents such as haloperidol and clozapine also reversed amphetamine's depressions of DA neuronal firing, as has been reported by other laboratories (1).
• the ability of neuroleptics to actually increase firing rates above control values has been associates (1,2) with the tendency of that agent to induce extrapyramidal side effects (EPS).
• EPS extrapyramidal side effects
• haloperidol which induces severe EPS in patients, increased firing rates to a level 64% greater than controls whereas clozapine, which induces far less EPS, (3), completely reversed the amphetamine effect but did not increase rates above controls (Table 2) .
• the amphetamine effect reversal by U-64,273A was not quite complete. This suggests that U-64,273A in addition to being a dopamine antagonist has a small amount (partial) of dopamine agonist activity.
• a partial agonist property is further suggested by the fact that U-64,273 is able to weakly inhibit the DA neuronal firing when given alone.
• U-64,273A Consistant with its having a minor amount of agonist activity, the overall behavioral effects of U-64,273A conform to that of a weak DA antagonist (Table 3). It antagonized apomorphine in the following tests: mouse climbing screen, locomotor stimulation in reserpinized mice, emesis in dogs and discriminative effects in monkeys. U-64,273A also antagonized d-amphetamine in the turning behavior of striatal-lesioned rats. However, it did not protect mice from a lethal dose of d-amphetamine nor did it block the stereotypic behaviors produced by apomorphine.
• U-64,273A affected locomotor activities in rodents in a way resembling both DA auto-receptor and postsynaptic receptor agonists. It suppressed conditioned avoidance behavior of rats with a limited efficacy. It produced no locomotor stimulation in reserpinized mice.
• the dimethylated derivative, U-65,556 is also of interest because it has antipsychotic activity with little or no propensity to produce EPS since it, 2,3-dihydro-N,N-dimethyl-1H-phenalen-2-amine, like U-64,273A, also reversed amphetamine's depressions of DA neurons without causing firing rates to increase over control.
• the 2-amino-phenalene compounds of this invention and those within the scope of the anti-psychotic method of use claims of this invention can be prepared by either a Diels-Alder type reaction, or by starting the reactions with an unsubstituted or appropriately substituted naphthalic anhydride, by procedures described herein, or by procedures known to those in the art.
• the Diels-Alder process variation starts from the selected commercially available non-R 3 -substituted or -R 3 -substituted 2-hydroxybenzaldehyde and 2-formyltetrahydrofuran, as outlined in Process Chart A, hereinbelow.
• a second usable process starts from an unsubstituted or R 3 -substituted naphthalene or naphthalenic anhydride and oxanilide and phosphorus pentachloride, or their equivalents.
• the R 3 -substitution if present, is present in a position such that in the desired 2-amino-2,3-dihydro-1H-phenalene end product compound an R 3 -substituent will be in the 4-, 5- or 6-position.
• the selection of the process can sometime depend upon the R 3 -substituent which is to be present In the end product compound.
• R 3 groups are obtained after progression of the process to a point where it is desirable to remove a protecting group, e.g., by the use of a starting material containing an R 3 -methoxy group , and later removal of the methyl group to form the end product 2-amino-2,3-dihydro-1H-phenalen-4-, 5- or 6-ol compound, which can then be further treated, if desired, to form esters, ethers and/or acid addition salts thereof.
• a protecting group e.g., by the use of a starting material containing an R 3 -methoxy group , and later removal of the methyl group to form the end product 2-amino-2,3-dihydro-1H-phenalen-4-, 5- or 6-ol compound, which can then be further treated, if desired, to form esters, ethers and/or acid addition salts thereof.
• the selected 2-formyl- (R 13 ) -phenol (A-1) where R 13 is, for example, a C 1 to C 4 -alkyloxy, hydroxy or R 4 -CH 2 -O group where R 4 is phenyl or substututed phenyl as defined hereinabove can be halogenated, for example, in step (A) with chlorine, bromine or iodine, preferably bromine, in the presence of a basic salt, such as an alkali metal acetate, and a mild acid such as acetic acid, followed by treatment with a halogenation promoter such as a stannous halide, e.g., stannous chloride, to form the 3-halo-2-hydroxy-R 3 -benazldehyde (A-2).
• a basic salt such as an alkali metal acetate
• a mild acid such as acetic acid
• the halogenated benzal dehyde (A-2) can then be treated in step B, with a hydroxy group protecting agent, e.g., with p-toluenesulfonyl chloride or bromide, to form the 3-bromo-2-(p-toluenesulfonyloxy)-R 3 -benzaldehyde (A-3).
• a hydroxy group protecting agent e.g., with p-toluenesulfonyl chloride or bromide
• furfuraldehyde (A-4) can be refluxed in step C, with ⁇ -alanine In a C 1 to C 3 -alkanol containing mixture, e.g., ethanol, for a sufficient time to form the 2-(2-nitroethenyl)furan compound (A-5).
• the 2-(nitroethenyl)furan compound (A-5) can be reduced in step D by known methods, e.g., with an alkali metal borohydride, to form the 2-(2-nitroethyl)furan (A-6).
• step E the hydroxy group protected-bromo-R 3 -benzaldehyde compound (A-3) and the 2-(2-nitroethyl)furan (A-6) can be reacted in step E, e.g., in a solvent mixture containing piperidine, acetic acid and a hydrocarbon solvent such as hexane, e.g., a commercially available hexane mixture such as SKELLYSOLVE B, to form the adduct (A-7).
• a solvent mixture containing piperidine, acetic acid and a hydrocarbon solvent such as hexane, e.g., a commercially available hexane mixture such as SKELLYSOLVE B
• the adduct A-7 can be reduced in step F by known means, e.g., with lithium aluminum hydride in an acid medium and an ether solvent such as tetrahydrofuran (THF), to form the corresponding amine compound (A-8), which can then be converted to a salt with an achiral acid, e.g., furmaric acid, or with a chiral acid, e.g., di-p-toluoyltartaric acid.
• This amine compound A-8 can, if desired, be resolved in step G at this point by known procedures, to form and separate the corresponding dextro (+) amine compound (A-9) and the levo (-) amine compound A-9.
• step H the racemic ( ⁇ ) mixture of the amine (A-9), or its separated (+) amine A-9 or (-) amine A-9 can be treated to protect the amine group, e.g., with acetonylacetone to form the aminenitrogen protecting 2,5-dimethyl pyrrolyl ring compound (A-10).
• the amino-protected compound A-10 can then be treated in step I with a deprotecting chemical, e.g., with phenyllithium, to remove the hydroxyl protecting group, here, e.g., the p-toluenesulfonyl group, to allow adduct formation or ring closure to occur to form the oxobridged, unsaturated ring structure compound (A-11).
• a deprotecting chemical e.g., with phenyllithium
• the oxa-bridged, ring unsaturated compound A-11 can then be reduced, in step J, e.g., by hydrogenation in the presence of a hydrogenation catalyst such as palladium on carbon to form the oxa-bridged, saturated ring compound (A-12).
• the oxa-bridged compound A-12 can be treated in step K with an aromatizing agent, e.g., with boron trifluoride etherate, to remove the oxa-bridge oxygen atom and to form the amino-nitrogen protected-2,3-dihydro-1H-R 3 -phenalene ring compound (A-13).
• the amino nitrogen protected compound A-13 can be treated in step L with a nitrogen-deprotecting agent, e.g., with hydroxyamine, to form the 2-amino-2, 3-dihydro-1H-R 3 -phenalene compound A-14.
• 2-amino-2,3-dihydro-1H-R 3 -phenalene compounds have anti-psychotic activity in their own right.
• these 2-aminophenalene compounds A-14 can be further processed to remove protecting groups, if desired, e.g., to remove alkyl groups from R 3 -C 1 to C 4 -alkyl groups to form the corresponding phenalen-4-, 5- or 6-ol compounds, and then purified as the free amine base compound, or converted to its appropriate acid addition salt one or more times for purification and isolation from its reaction mixture, and then to the selected pharmaceutically acceptable acid addition salt for further purification and crystallization for use in making the pharmaceutical compositions thereof, for use as an antipsychotic drug product.
• the primary 2-amino nitrogen of compound A-14 can be alkylated in step M, e.g., with appropriate halogenated hydrocarbons such as a C 1 to C 4 -alkyl halide such as a methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl bromide in amounts and for a time sufficient to form the desired corresponding 2- (mono- or (di-alkylamino)-2,3-dihydro-1H-phenalene com ⁇ pound, or with a selected X-C 3 to C 5 -X dihaloalkane where X is chl ⁇ oro, bromo, or iodo, e.g., with 1,3-dibromopropane, 1,4-dibromobutane, 1,5-dibromopentane to form the corresponding 1-azetidine, 1pyr
• Such ring compounds can also be ring substituted on ring carbons thereof with 1 to 2-methyl groups, as ethyl group, a methoxy group or a hydroxy group by the corresponding selection of the dibromo-substituted alkane reactant.
• step N one can form any of a variety of acid addition salt forms of said compounds A-16 by known dissolution, purification and crystallization procedures.
• the unsubstituted or R 3 -substituted naphthalene (B-1), e.g., an R 13 -substituted naphthalene where R 13 is a C 1 to C 4 -alkyloxy, hydroxy or an R 4 -CH 2 -O-group where R 4 is phenyl or substituted phenyl as defined hereinabove, can be reacted with the bis[ (N-phenyl) (chloro)-methylimine] (B-2) and aluminum chloride (B-3), or their equivalents, to form the R 13 -naphthalene anhydride compound (B-4).
• the anhydride (B-4) can then be ring opened with base and esterified to form the 1,8-diester compound (B-5).
• the diester (B-5) can then be reduced, e.g., with lithium aluminum hydride, to form the R 3 -naphth-1,8-yldimethanol compound (B-6).
• the di-ol compound B-6 can then be halogenated, e.g., with phosphorus tribromide, to form the R 13 -naphth-1,8-ylbis(methyl bromide) compound (B-7).
• the di-bromomethyl compound (B-7) can then be ring-closed and esterified in the 2-position of the 2,3-dihydro-1H-R 3 -phenalene compound, e.g., by treatment with a malonate ester in the presence of an alkali metal hydride to form one or both of R 13 -phenalene ring esters (B-8) and (B-9).
• the ester intermediate (B-8 and/or B-9) can then be de-esterified to form the 2-dicarboxy-R 13 -phenalene compound (B-10).
• the di-carboxy compound B-10 can be heated to a temperature sufficient to remove one carboxyl group and to form the 2-mono-carboxy R 3 -phenalene compound (B-11).
• the 2-carboxy compound (B-11) can be treated with diphenyl phosphorus azide in the presence of a C 1 to C 8 -alkanol, preferably tert-butanol, to form the corresponding 2-alkyloxycarbonylamino)phenalene (2-carbamate) compound (B-12).
• the 2-carbamoyl compound (B-12) can be treated with acid, e.g., trifluoroacetic acid, to form the 2-amino-R 3 -phenalene compound (B-13).
• the chemical operator at this point has the options of treating the primary 2-amino compound (B-13) to remove protecting groups, or to alkylate the primary 2-amino nitrogen of compound B-13 to form the desired 2-(N-mono- or N,N-di-substituted amino) -2,3-dihydro-1H-R 3 -phenalene compounds (B-14).
• the 2-amine compound B-13 can be treated with formaldehyde and alkali metal borohydride, by known methods, to form the 2-(N-methylor N,N-dimethylamino)-2,3-dihydro-1H-R 3 -phenalene compound (B-14).
• the selected 2-amino-2,3-dihydro-1H-phenalene compound (B-14) can be converted to an acid addition salt forms thereof successively, for isolation, purification, and pharmaceutical composition preparation purposes.
• Processes for preparing compounds of the invention are further exemplified by detailed Examples 38 to 43 and Charts C through G which illustrate in chemical structure flow sheet formats how compounds of this invention were and can be made.
• Examples 38 to 40 together with Charts C, D and E illustrate and exemplify how 6-position substituted-2,3-dihydro-1H-phenalen-2-amine compounds, useful as antipsychotic drugs can be prepared.
• Examples 41 and 42 together with Charts F and G exemplify and illustrate how some of the preferred 5-position substituted 2,3-dihydro-1H-phenalen-2-amine compounds can be prepared.
• compositions containing a new formula I compound as an active ingredient in a pharmaceutical carrier are useful in pharmaceutical dosage unit forms of the formula I compounds for local (topical) and systemic administration (oral, rectal and parenteral administration form) in therapy for treating and alleviating symptoms of psychoses in humans and valuable animals, including dogs, cats and other commercially valuable and domestic animals.
• dosage unit form refers to physically discrete units suitable as unitary dosages for mammalian subjects, each unit containing a predetermined quantity of the essential active ingredient compound of this invention calculated to produce the desired effect, in combination with the required pharmaceutical means which adapt the said ingredient for systemic administration.
• the specification for the novel dosage unit forms of this invention are dictated by and directly dependent on the physical characteristics of the essential active ingredient and the particular effect to be achieved in view of the limitations inherent in the art of compounding such an essential active material for beneficial effects in humans and animals as disclosed in detail in this specification under exemplified embodiments, these being features of the present Invention.
• suitable dosage unit forms in accordance with this invention are tablets, capsules, orally administered liquid preparations in suitable liquid vehicles, sterile preparations in suitable liquid vehicles for intramuscular and intravenous administration, suppositories, and sterile dry preparations for the extemporaneous preparation of sterile injectable preparations in a suitable liquid vehicle.
• suitable, solid diluents or carriers for the solid oral pharmaceutical dosage unit forms are selected from the group consisting of lipids, carbohydrates, proteins and mineral solids, for example, starch, sucrose, lactose, kaolin, dicalcium phosphate, gelatin, acacia, corn syrup, corn starch, talc and the like.
• Capsules are filled with compositions of the selected formula I compound or salt thereof Ingredients in combination with suitable diluents and excipients, for example, edible oils, talc, calcium carbonate and the like and also calcium stearate.
• suitable diluents and excipients for example, edible oils, talc, calcium carbonate and the like and also calcium stearate.
• Liquid preparations for oral administration are prepared in water or aqueous vehicles which advantageously contain suspending, agents, for example, methylcellulose, acacia, polyvinylpyrrolidone, polyvinyl alcohol and the like.
• the injectable formulation In the case of injectable forms, the injectable formulation must be sterile and must be fluid to the extent that easy syringeability exists.
• Such preparations must be stable under the conditions of manufacture and storage, and ordinar ily contain in addition to the basic solvent or suspending liquid, preservatives in the nature of bacteriostatic and fungistatic agents, for example, parabens, chlorobutanol, benzyl alcohol, phenol, thimerosal, and the like.
• preservatives in the nature of bacteriostatic and fungistatic agents, for example, parabens, chlorobutanol, benzyl alcohol, phenol, thimerosal, and the like.
• osmotically active agents for example, sugars or sodium chloride in isotonic concentrations.
• Carriers and vehicles include vegetable oils, ethanol, polyols, for example, glycerol, propylene glycol, liquid polyethylene glycol, and the like.
• any solid preparations for subsequent extemporaneous preparation of sterile injectable preparations are sterilized, preferably by exposure to a sterilizing gas, for example, ethylene oxide.
• a sterilizing gas for example, ethylene oxide.
• the aforesaid carriers, vehicles, diluents, excipients, preservatives, isotonic agents and the like constitute the pharmaceutical means which adapt the preparations for systemic administration.
• a daily dose of 1 to 700 mg is indicated, preferentially 10 to 200 mg; in units of two or three or four subdivided doses , and the exact amount is adjusted based on the weight, age and condition of the patient.
• the pharmaceutical dosage unit forms are prepared in accordance with the preceding general description to provide from about 0.5 mg to about 100 mg of the essential active ingredient per dosage unit form.
• the amount of the essential active ingredient provided in the pharmaceutical dosage unit forms is based on the finding that the effective amount of 2-N,N-(di-n-propylamino) -2,3-dihydro-1H-phenalen5-ol, a representative example of the compounds of the invention and acid addition salts thereof, for obtaining an antipsychotic effect in humans is expected to be within a range from about 0.01 mg/kg to about 10 mg/kg, preferably 0.06 to 1.0 mg/kg.
• the active ingredients of this invention can also be compounded in combination with other ingredients.
• the amount of such other active ingredients is to be determined with reference to the usual dosage of each such ingredient.
• these active compounds can be combined with hypotensive agents such as ⁇ -methyldopa (100-250 mg); with diuretics such as hydrochlorothiazide (10-50 mg); tranquilizers such as meprobamate (200-400 mg), diazepam (2-10 mg), muscle relaxants, such as carisoprodol (200-400 mg) .
• the compounds listed below were tested and found to have possible useful anti-psychotic activity properties as indicated by their having CNS test result, ED 50 numbers of less than 50 mg/kg values in the known Hypothermia and/or the Apomorphine gnawing test.
• the lower ED 50 data numbers in one test or the other is believed to be an indication of whether the compound acts by pre-synoptic agonist mechanism or by a dopamine receptor antagonist mechanism in accomplishing its antipsychotic drug effect. Most of these compounds also show some analgesic potency in standard analgesic laboratory animal tests.
• a group of four CF-1 male mice (18-22 g each) was injected intraperitoneally with the test compound prepared in 0.25 percent w/v methylcellulose in water solution. After 45 min, abdominal temperature of each mouse was measured using a thermister probe.
• a control group of four mice was treated with vehicle only and the temperature of the control group was taken in a similar manner.
• a compound was considered to have a significant effect on body temperature if the mean temperature in the test compound treated group deviated more than 3.5oC from the mean temperature of the parallel control group. Stimulants tend to elevate temperatures; depressants tend to lower body temperature.
• the compound ( ⁇ )2-(N,N-di-n-propylamino)-2,3-dihydro-1-phenalen-5-ol of this invention caused hypothermia in the test mice, with a calculated ED 50 of 1 mg/kg of body weight.
• test data appear to suggest that the hypothermic effect of ( ⁇ )2-(N,N-di-n-propylamino) -2,3-dihydro-1H-phenalen-5-ol is the result of the activation of dopamine receptors, since the known dopamine blocker, haloperidol, also significantly blocks the hypothermia effect induced by 2- (N,N-di-n-propylamino)-2,3-dihydro-1H-phenalen-5-ol.
• the known alpha-2 adrenergic blocker, yohimbine did not alter the 2-(N,N-di-n-propylamino)-2,3-dihydro-1H-phenalen-5-ol induced hypothermia, but yohimbine did block the hypothermia usually induced by the known antihypertensive clonidine.
• the dopamine agonist, apomorphine was similar to 2-(N,N-di-n-propylamino)-2,3-dihydro-1H-phenalen-5-ol in regard to antagonism by these agents.
• tests for helping to assess possible antipsychotic drug use activity include tests which (1) determine receptor binding activity of the test compound, or (2) antagonize the action of Damphetamine. Activity in any one of these four tests indicates possible antipsychotic activity interest, based upon possibly different pharmacological mechanisms of action.
• a rat brain homogenate was prepared (1) by homogenizing a whole rat brain minus the cerebellum in 10 ml of 0.05M THAM-HCl, pH 7.4, using a Polytron at a setting of 7 for 30 sec. and centrifuging at 15,000xg for 10 min. The supernatant was discarded, the pellet resuspended in 10 ml of buffer using the Polytron for 10 sec, and the centrifugation repeated. The pellet was resuspended and diluted to 100 times the original tissue weight with buffer. Then 100 ml of the homogenate was diluted to 400 ml with buffer.
• test drug was weighed out in a scintillation vial in a 1-5 mg ammount. They were dissolved by adding 0.5 ml of N-N-dimethylformamide of (DMF) and then 0.05 ml of 1M acetic acid, and vortexed to solubilize the drug. Then 10 ml of deionized and filtered water was added to the required volume. All compounds were tested at a single concentration of 1 uM.
• DMF N-N-dimethylformamide of
• Samples were prepared for incubation using an 3 H-spiperone (antipsychotic). Incubation was conducted at 30°C for 30 min. on a shaking water bath. Every 30 sec, 24 tubes were filled with 1 ml of homogenate and put into the bath (this is done every 3 min. until all tubes are in the bath). Upon completion of the incubation procedure, the samples are filtered and rinsed. The punched filters are dropped into vials, which are in turn filled with ACS liquid scintillation fluid and capped and counted in a liquid scintillation counter. Counting data is recorded and analyzed.
• 3 H-spiperone antipsychotic
• Results are expressed as percent decrease from control. A decrease from control may indicate antipsychotic activity.
• Data for testing compounds of Examples 38 to 41 are set forth in Table 1.
• the methods for preparing the compounds of this invention are further exemplified by the following detailed examples which are not intended as being limiting on the scope of the invention. All temperatures are in degrees Celcius unless otherwise indicated. Letter symbols are used in some places for brevity in references to common chemical reagents and analytical procedures. For example, IR means infrared, UV means ultraviolet, NMR means nuclear magnetic resonance spectral analyses. THF means tetrahydrofuran, ether, used alone, means diethyl ether, petroleum ether means a commercial solvent having the indicated boiling point range.
• MeOH means methanol
• ETOAC means ethyl acetate, and the like.
• Example 1 2,3-Dihydro-N,N-dimethyl-1H-phenalen-2-amine, and its monohydrochloride. Sodium cyanoborohydride (0.42 g; 6.8 mmole) was added- to a solution of 2,3-dihydro-N-monomethyl-1H-phenalen-2-amine (0.71 g; 3.4 mmole) and 1.7 ml of 37% aqueous formaldehyde solution in 17 ml of acetonitrile and 6.8 ml of methanol. The pH of the mixture was adjusted to 7 with acetic acid.
• the chloroform layer extract was washed with saturated sodium chloride solution, separated therefrom, and the organic liquid layer was dried with magnesium sulfate, and evaporated to leave as residue 0.4 g of the titled amine as an oil.
• An NMR spectrum was consistent with the named amine.
• the amine oil was dissolved in diethyl ether, the resulting solution was filtered and treated with a hydrogen chloride in diethyl ester solution to form the titled amine hydrochloride salt.
• the hydrochloride salt was crystallized from a methanol/diethyl ether mixture at -10oC, weight 0.28 g, m.p. 283-284oC (dec).
• the combined filtrate was acidified with 2.2 liters of concentrated hydrochloric acid.
• the resulting suspension was allowed to stand for 1 hr, filtered and the filter solid was washed with water to obtain 86 g (71% yield) of the herein sub-titled anhydride compound, m.p. 219-220°C.
• UV sh 214 nm (70,700), ⁇ max 233 (67,950), sh 275 (4,500), 284 (6,000), 296 (5,350), 324 (2,800), 337 (3,050).
• a solution of diethylmalonate (4.96 g; 0.031 mole) in 30 ml of tetrahydrofuran was added during 5 min to a suspension of sodium hydride (1.48 g; 0.031 mole of 50% suspension in mineral oil, washed with petroleum ether (30-60°) in 30 ml of tetrahydrofuran. The mixture was stirred for 30 min. It was cooled to -15°, a solution of the dibromo compound from part F hereinabove (10.3 g; 0.03 mole) in 30 ml of tetrahydrofuran was added during 10 min at -15°, stirred for 2 hr at room temperature. Another 0.031 mole of sodium hydride was added at room temperature.
• Diphenyl phosphoryl azide (2.75 g; 0.01 mole) and triethylamine (1.11 g; 0.011 mole) were added to a suspension of the 4-methoxy-2-carboxy-2,3-dihydro-1H-phenalene acid, from part I hereinabove (2.4 g, 0.01 mole) in 50 ml of tert-butyl alcohol. The mixture was stirred at room temperature for 15 min and then refluxed for 22 hr. The resulting suspension was evaporated to remove solvent, and the residue was taken up in a methylene chloride/water mixture, and filtered to remove a small amount of solid.
• the organic liquid phase was separated and washed with water, with saturated sodium chloride solution, dried with magnesium sulfate, and evaporated to remove sol vent.
• the residue was extracted with 4 x 100 ml portions of boiling SKELLYSOLVE B brand of hexanes to separate the product form an insoluble yellow oil.
• the extracts were combined and concentrated to about 50 ml, and the residue was allowed to sit to allow crystallization to occur. There was obtained 2.8 g of the crude hereinabove sub-titled compound, m.p. 146-148°C. After filtration, a second crop weighing 0.12 g, same melting point of the same compound was obtained from the filtrate. This material was pure enough for use in the next step of the process.
• Trifluoroacetic acid 50 ml, was added to a 17.7 g (0.056 mole), non-chromatographed portion of the 4-methoxy-2-(tert-butoxycarbonylamino)-2,3-dihydro-1H-phenalene, obtained as described in part J hereinabove.
• the resulting solution was stirred for 0.5 hr.
• the solution was quenched with ice, followed by the addition of 20% w/v sodium hydroxide solution, and then the mixture was extracted with chloroform.
• the chloroform extract phase was washed with water, with saturated sodium bicarbonate solution, with saturated sodium chloride salt solution, dried with magnesium sulfate and evaporated.
• UV sh 215 (22,750), ⁇ max 231 (66,100), sh 263 (2,450), sh 274 (4,400), 283 (6,300), 296 (6,000), sh 310 (1,450), 323 (2,458), sh 335; 337 (3,000).
• the hydrochloride salt of this amine was prepared in diethyl ether with hydrogen chloride in diethyl ether, and this salt was crystallized from a methanol/diethyl ether mixture, giving 2.21 g 780% yield) of the titled amine hydrochloride salt, m.p. 234-235°C, which was raised to 235-236° upon recrystallization.
• 5-SUBSTITUENT SERIES Example 7 2-Amino-5-methoxy-2,3-dihydro-1H-phenalene, and its hydrochloride salt.
• Dimethyl sulfate (187 g; 1.48 mole) was added to a. suspension of 3-hydroxy-1,8-naphthalic anhydride (51 g; 0.24 mole) from Part B hereinabove in 1200 ml of methanol.
• a solution of potassium hydroxide (86.8 g; 1.55 mole) in 1200 ml of methanol was added during 40 min, keeping the temperature at 25°C, and stirring was continued at 25°C for 2 hr.
• Halfway through the addition of the potassium hydroxide solution a reaction mixture solution was obtained followed by a suspension.
• the resulting mixture was evaporated in vacuo at 35°C and the residue was taken up in 300 ml each of water and diethyl ether.
• LAH lithium aluminum hydride
• the aqueous layer was extracted with diethyl ether (2 x 25 ml) , and the combined organic solution was washed with water, saturated sodium bicarbonate solution (25 ml), saturated salt solution, dried (magnesium sulfate) and evaporated to leave the sub-titled compound as a colorless solid, 2.45 g (72% yield), m.p. 118-122°.
• the analytical sample was prepared from diethyl ether at -18°, colorless prisms, m.p. 129-130°.
• UV sh 230 (33,500), 5 max 239 (34,450), sh 296 (7,050), 304 (7,200), 333 (3,950), 344 (4,350).
• HaH sodium hydride
• petroleum ether having a b.p. of 30-60°C
• UV ⁇ max 232 (53,650), sh 259 (2,950), sh 269 (4,400), 280 (5,800), 292 (5,150), 319 (1,750), sh 328 (1,700), 334 (2,500).
• the resulting suspension was filtered to remove the above named insoluble urea, (7.29 g;, see below).
• the filtrate was separated, the aqueous phase was extracted with chloroform, and the combined organic liquid phases was washed with 5% w/v sodium hydroxide aqueous solution (3 x 100 ml) , with water and with saturated sodium chloride salt solution and then dried over magnesium sulfate and evaporated.
• UV ⁇ max 233 (60,700), sh 260 (3,000), 269 (4,550), 279 (5,900), 291 (5,200), 317 (1,800), 332 (2,500).
• Trifluoroacetic acid 85 ml, was added to 30.5 g (0.0958 mole) of the tert-butyl carbamate compound, prepared as described in part I hereinabove. The resulting solution was stirred for 20 min. Ice was then added, and the resulting mixture was made pH basic with 20% w/w sodium hydroxide in water solution and stirred for 1 hr at room temperature. The mixture was extracted well with chloroform, the chloroform extract was separated and washed with water, with saturated sodium chloride solution; dried with magnesium sulfate, and evaporated to give 18.8 g (92% yield) of the above sub-titled amine as a brown oil.
• This amine oil was converted to its hydrochloride salt in methanol with 1.5 N hydrogen chloride in diethyl ether solution to give 18.11 g of the above titled hydrochloride as colorless needle crystals, m.p. 252°C (dec). It was associated with about 0.25 water of hydration.
• UV ⁇ max 233 (58,950), 258 (2,850), 269 (4,300), 278 (5,450), 290 (4,600), 318 (1,650), 333 (2,300).
• IR NH 3 + 2786, 2691, 2614, 2531, 2487, 2033; NH 3 + /C C 1621, 1607, 1591, 1515, C-O 1263, 1195, 1168, 1161, 1102, 1026; aromtic 834,751.
• NMR (CDCl 3 +CD 3 OD) ⁇ 3.25-3.45 (m,7,CH 2 ,CH,NH 2 ), 3.89 (s,3,OCH3), 6.85-7.65 (m, 5, aromatic).
• the purple gummy oil which resulted was separated by filtration through a filter aid, CELITE ® .
• the yellow filtrate was diluted with diethyl ether to cloudiness, seeded and allowed to crystallize at room temperature.
• the resulting crystalline solid product was separated from supernatent liquid and washed with a methanol/diethyl ether (1:3 v/v mixture) to obtain 1.23 g (46% yield) of the titled amine hydrobromide salt, m.p. 226-227°C (dec).
• UV ⁇ max 232 (55,900), sh 262 (2,500), 277 (4,150), 282 (5,600), 294 (5,050), 324 (2,150), 336 (2,600).
• UV ⁇ max 232 (56,150), sh 259 (3,000), sh 269 (4,450), 279 (5,850), 290 (5,100), 318 (1,850), 333 (2,550).
• UV ⁇ max 231 (54,150, sh 262 (2,650), sh 273 (4,200), 282 (5,800), 294 (5,300), 324 (2,250), 336 (2,700).
• IR OH 3167; NH + 2738, 2647, 2520; C C 1629, 1622, 1605, 1593, 1513; C-O 1279, 1166, 977; aromatic 860, 798, 777.
• the solid was recrystallized nineteen times , each time converting a sample of the tartarate salt to the free base, then to the hydrochloride and checking the rotation thereof.
• [ ⁇ .] D 25 + 11.22 (c 0.74, MeOH) was observed, the di-p-toluoyl tartarate was recrystallized 4 times without any further change in the rotation of the hydrochloride.
• the (+) di-p-toloyl-D-tartaric acid salt melted at 162-163° dec, UV, IR and mass spec, were .in accord. [ ⁇ ] D 25 + 82.41 (c 0.705, MeOH).
• Example 14 Cleavage of methyl group from (+) -2- (di-n-propylamino)-5-methoxy-2,3-dihydro-1H-phenalene to form (+)-2- (di-n-propylamino)-5-hydroxy-2,3-dihydro-1H-phenalene.
• Example 16 (+)2-(Dipropylamino)-2,3-dihydro-1H-phenalen-5-ol monobromide.
• This example illustrates a Diels-Alder type process for preparing R 3 -substituted-2,3-dihydro-1H-phenalen-2-amine compounds of this invention starting from a selected 2-hydroxybenzaldehyde.
• the aqueous phase solution was separated from the diethyl ether liquid phase and again extracted with diethyl ether.
• the aqueous and diethyl ether liquid phases were separated.
• the combined diethyl ether liquid phases were washed with water, saturated sodium chloride solution, and then dried over magnesium sulfate.
• the resulting dried solution was subjected to vacuum to remove solvent to leave as a residue the above named compound as a brown oil.
• An NMR spectral analysis confirmed the presence of the named compound. Distillation of the brown oil, and the taking of fractions thereof as follows gave the following weight amounts of named product. bp/mm (Hg) Pressure Wt of Product 1. (forerun) 0.41 g
• the reaction mixture was diluted to 300 ml with methylene chloride, silica gel (50 g, 70-230 mesh) was added, and the mixture was stirred for 2.5 hr. Ethereal HCl (about 5 mmol of HCl) was added and the mixture was stirred for 30 min. The mixture was filtered, and the silica gel was washed several times with methylene chloride. The combined organic liquid phases were evaporated to dryness to give 3.72 g of a yellow oil. Crystallization from methanol gave a yellow solid (2.74 g, 65%; m.p. 116oC). The NMR, IR and UV spectra were consistent with the titled compound.
• the filtrate from the first crystallization was evaporated to dryness and the residue was partitioned between diethyl ether and 15% w/v sodium hydroxide aqueous solution.
• the aqueous phase was separated and extracted with diethyl ether.
• the combined diethyl ether organic liquid phases were washed with 15% w/v sodium hydroxide aqueous solution and saturated sodium chloride solution and then dried with magnesium sulfate.
• the solvent was removed in vacuo to leave the resolved amine as a yellow brown oil, 34.28 g.
• the solvent was removed in vacuo and the residue was partitioned between 5% w/v sodium hydroxide solution and diethyl ether.
• the aqueous phase was extracted with diethyl ether.
• the combined organic liquid phases were washed with water and extracted with 25 ml of 10% v/v aqueous hydrochloric acid solution.
• a precipitate was formed which solubilized by added water, about 50 ml.
• the aqueous and organic liquid layers were separated and the diethyl ether layer was extracted again with 25 ml of 10% hydrochloric acid solution.
• the acid extracts were washed with diethyl ether and basified with 40% w/v sodium hydroxide solution while cooling in ice.
• the resulting milky mixture was extracted three times with di ethyl ether.
• the resulting ether extracts were combined and washed with saturated sodium chloride solution and dried with magnesium sulfate.
• the solvent was removed in vacuo to leave the sub-titled compound as a colorless oil which solidified upon standing, and weighed 1.03 g (79 percent yield). An NMR spectrum of a sample thereof was consistent for this sub-titled compound.
• the larger, first crop was converted to its hydrobromide salt by dissolving the 2- (di-n-propylamino) -5-hydroxy-2,3-dihydro-1H-phenalene in diethyl ether, and adding 30% hydrogen bromide in acetic acid until precipitation is complete.
• the precipitate was filtered from the liquid mixture and recrystallized from a methanol/diethyl ether mixture to obtain the hydrobromide salt as gray needles, m.p. 235-236°C (dec), 16 g.
• Example 17 (+) 2-(Di-n-propylamino)-5-Hydroxy-2,3-dihydro-1H- phenalene.
• Example 16 Following the procedure of Example 16 and using the (-) resolved isomer of 2- [2-amino-3-(2-furanyl)propyl]-6-bromo-4-methoxyphenol, 4-methylbenzenesulfonate (ester) from Example 16, part G, the optical rotation of which is -9.92°, and following generally the reaction steps set forth in parts H to N of Example 16 hereinabove, there is obtained the (+)-2-(di-n-propylamino)-5-hydroxy-2,3-dihydro-1H-phenalene and its hydrobromide salt.
• 6-SUBSTITUENT SERIES Example 18 2-Amino-6-bromo-2,3-dihydro-1H-phenalene, and its hydrochloride.
• the diester, diethyl IH-phenalene-2,2 (3H)dicarboxylate, 1.56 g, 5.0 mmol) was dissolved in chloroform (20 ml) and ferric chloride (0.27 g, 1.7 mmol) was added.
• a solution of bromine (0.86 g, 5.4 mmol) in chloroform (10 ml) was added, and the mixture was stirred at room temperature for 2.5 hr.
• the reaction mixture was washed with water, saturated sodium bicarbonate, saturated sodium chloride and dried (magnesium sulfate).
• the 6-bromo diester from part A hereinabove (185.3 g, 0.47 mol) was dissolved in methanol (1,300 ml) and added to a solution of potassium hydroxide (263.2 g, 4.7 mol) in water (1,300 ml), and the mixture was stirred at reflux for two hr.
• the methanol was removed in vacuo, and the aqueous mixture was diluted with 500 mls of water and extracted twice with ether.
• the aqueous solution was acidified with concentrated HCl, and the resulting white precipitate was fil- tered, washed with water, and dried in vacuo at 50°C. to give 157 g (100%) of the subtitled diacid.
• NMR CDCl3 52.42 (s, 6, NMe 2 ), 2.5-3.35 (m, 5, CH 2 -CH-CH 2 ), 7.02- 8.10 (m, 5, aromatic).
• the titled hydrochloride was prepared in diethyl ether with ethereal HCl, m.p. 277-278oC dec, unchanged on recrystallization from methanol-ether.
• IR-CH 3063, 3034, 3020, 3009; NH + 2643, 2571, 2524, 2478; C C 1612, 1598, 1572, 1505, 1493; other 966; aromatic 815, 758.
• Example 20 1-(6-Bromo-2,3-dihydro-1H-phenalen-2-yl)azetidine.
• the aqueous layer was extracted with chloroform.
• the combined chloroform layers were washed with water and saturated sodium chloride aqueous solution, and dried with magnesium sulfate.
• the dried organic liquid phase was evaporated.
• a Beilstein test of the residue for halogen was positive.
• the above oil residue was heated with 15% sodium hydroxide w/v in water solution at 95°C for two hr and worked up as above.
• the resulting crude oil product (3.4 g) was subjected to low performance liquid chromatography (LPLC) using a 300 ml. column packed with 230-400 mesh size silica gel particles and using 3% v/v methanol in chloroform mixture, also containing 0.5% v/v ammonium hydroxide solution as eluting liquid. Twenty ml. fractions were collected. Fractions 1 to 19 gave no pertinent material. Fractions 20 to 31 gave 1.18 g of the titled -azetidine derivative compound as a brown oil.
• LPLC low performance liquid chromatography
• UV sh 214 nm (24,650), sh 225 (50,850), ⁇ max 229 (64,750), sh 274 (4,550), 284 (7,850), 295 (9,900) 306 (7,100), 312 (5,600), sh 320 (1,450), 326 (1,350).
• the chloroform liquid layer was separated from the aqueous phase and washed with water, with saturated sodium chloride aqueous solution and then dried with magnesium sulfate, and evaporated to give 0.86 g of the crude titled -pyrrolidine derivative compound as a brown oil.
• UV sh 214 (26,200), ⁇ max 229 (57,950), sh 276 (4,850), sh 287 (8,150), 297 (10,350), 307 (7,600), 312 (6,600), sh 321 (2,200), 326 (1,750).
• the residue was extracted with three 100 ml portions of boiling 20% v/v diethyl ether in petroleum ether (b.p. 30-60°C), the extract was concentrated to about 50 ml, the residue was cooled in ice, diethyl ether was added to clarify the liquid and the residue was allowed to crystallize to give 2.51 g of the crude subtitled compound, m.p. 89.5-91°C.
• the filtrate was evaporated and the residue, 5 g, was chromatographed on 500 g of silica gel using 10% v/v ethyl acetate in cyclohexane mixture as eluting liquid, collecting 30 ml fractions.
• the maleic acid salt of this amine was prepared in diethyl ether witn an equimolar amount of maleic acid and was recrystallized from methanol/diethyl ether, m.p. 193-194°C.
• IR NH + /acid OH 2794, 2731, 2626, 2505; CO 2 -/C C/CH def. 1628, 1601, 1578, 1514, 1462, 1350; C-O 1192, 1043, 1037, 987; aromatic 875.
• Eyamp. g 24 [2,3-Dihydro-2-(methylamino)-1H-phenalen-6-yl]-(phenyl)methanone, and its methanesulfonate salt.
• A A preparation of 6-benzoyl-2,3-dihydro-1H-phenalen-2-yl carbamic acid ethyl ester.
• Benzoyl chloride 3.51 g (0.025 mole) was added to a solution of 5.1 g (0.02 mole) of 2-(ethoxycarbonylamino)-2,3-dihydro-1H-phenalene in 100 ml of ethylene chloride. While keeping the temperature of the mixture at 20-25°C, 9.33 (0.025 mole) of aluminum trichloride was added portionwise over 5 min. The mixture was stirred at room temperature for two hr. The mixture was cooled in ice, ice was added followed by 250 ml of 10% v/v hydrochloric acid solution.
• the resuiting mixture was extracted with diethyl ether and the organic liquid phase was washed twice with aqueous sodium bicarbonate solution, once with saturated sodium chloride solution, then dried with magnesium sulfate and evaporated.
• the residual brown oily solid, 6 g was subjected to LPLC purification using a 635 ml Michel-Miller column and 230-240 mesh silica gel. Elution of the column with a 5% v/v ethyl acetate in cyclohexane mixture as elution liquid separated impurities. Fractions 1 to 50 (30 ml each) contained impurities.
• NMR (CDCl 3 ) 5 1.22 (t, 3, CH 3 , J 7.1 Hz).
• Example 25 1,[2,3-dihydro-2-(methylamino)-1H-phenalen-6-yl]- ethanone and its monohydrochloride.
• Example 26 N-[2,3-Dihydro-6-(2-methyl-1,3-dioxolan-2-yl)-1H- phenalen-2-yl] dimethylamine.
• Sodium cyanoborohydride (NaCNBH 3 ) (0.126 g; 2 mmole) was added to a solution of 2,3-dihydro-N-methyl-6-(2-methyl-1,3-dioxan-2-yl)- 1H-phenalen-2-amine, free base from Example 23 hereinabove (0.283 g; 1 mmole) and 0.5 ml of aqueous 37% formaldehyde solution in 5 ml of acetonitrile and 2 ml of methanol.
• Example 27 1-[2,3-Dihydro-2-(dimethylamino)-1H-phenalen-6-yl]- ethanone butanedioate (1:1).
• Example 28 [2-(Di-methylamino)-2,3-dihydro- ⁇ -methyl-1H-phenalen- 6-yl]methanol and its hydrochloride, or named another way - 1-[2-(Dimethylamino)-2,3-dihydro-1H-phenalen-6- yl]-1-ethanol, and its hydrochloride salt.
• LAH lithium aluminum hydride
• the hydrochloride of this amine was prepared in ethereal HCl, and was crystallized from MeOH-ether at -10°, m.p. 241-242° dec. UV ⁇ max 212 (25,300), sh 225 (47,050), 231 (65,150), sh 282 (6,750), 291
• the mixture was refluxed for 1 hr; cooled in ice, and treated in succession with 0.5 ml of water, with 0.5 ml of 15% w/v sodium hydroxide solution, and 1.5 ml of water.
• the mixture was stirred 1 hr at room temperature, filtered, the filter cake was washed well with THF, and the combined organic filtrate and wash liquid was evaporated to leave as residue 0.27 g of the titled di-methyl amine compound.
• the IR spectrum showed no carbonyl from the starting material.
• Example 30 [2,3-Dihydro-2-(dimethylamino)-1H-phenalen-6-yl)- (phenyl)methanone, and its (Z)-2-butenedioate (maleate) salt.
• Jones reagent chromium trioxide/water/conc sulfuric acid
• 0.2 ml; 0.55 mmole was added dropwise to a solution of the methanol, [2,3-dihydro-2-(N,N-dimethylamino)-1H-phenalen-6-yl]-(phenyl)methanol, from Example 27 hereinabove (0.26 g; 0.82 mole) in 10 ml of acetone.
• the maleate salt of diamine was prepared in diethyl ether using an equimolar amount of maleic acid, and was crystallized from a methanol/diethyl mixture, m.p. 168-169o.
• the maleate salt of diamine was prepared in diethyl ether using an equimolar amount of maleic acid, and was crystallized from a methanol/diethyl mixture, m.p. 168-169°.
• Example 33 One thousand two-piece hard gelatin capsules for oral use, each capsule containing 20 mg of ( ⁇ ) 2- (N,N-propylamino)-2,3-dihydro-1H-phenalen-5-ol succinate as the essential active ingredient are prepared from the following ingredients:
• the finely powdered materials are mixed thoroughly, then filled into hard gelatin capsules of appropriate size.
• One-piece soft elastic capsules for oral use each containing 100 mg (+)-2-(N,N-di-n-propylamino)-2,3-dihydro-1H-phenalen-5-ol succinate as the essential active ingredient are prepared in the usual manner by first dispersing the active material in sufficient corn oil to render the material capsulatable.
• An aqueous oral preparation containing in each teaspoonful (5 ml) 80 mg of ( ⁇ ) 2-(N,N-di-n-propylamino-5-methoxy-2,3-dihydro-1H-phenalene succinate as the essential active ingredient is prepared from the following ingredients: Essential active ingredient 160 gm
• Magnesium stearate 1.5 gm The ingredients are thoroughly mixed and slugged. The slugs are broken down by forcing through a screen and the resulting granules are then compressed into tablets.
• Example 37 A sterile, aqueous suspension for intramuscular injection and containing in each milliliter 50 mg of ( ⁇ )-2-(N,N-di-n-propylamino)-2,3-dihydro-1H-phenalen-5-ol succinate as the essential active ingredient is prepared from the following ingredients: Essential active ingredient 5 gm
• Example 38 2,3-Dihydro-6-methyl-N,N-dipropyl-1H-phenalene-2- amine.
• A Preparation of 6-Bromo-N-(2,5-dimethylpyrrol-l-yl)2,3-dihydro-1H-phenalen-2-amine.
• the 6-bromo-2,3-dihydro-1H-phenalen-2-amine hydrochloride from Example 18 (10 g) was partioned between ether and dilute sodium hydroxide to give the free base (8.45 g, 0.0322 mol).
• the amine was combined with acetonylacetone (2,5-hexanedione; 7.5 mls, 0.064 mol), propionic acid (0.58 ml, 7.8 mmol), and benzene (150 mls), and the mixture was refluxed through a Dean-Stark trap for 17 hours.
• Silica gel 80 mls, 0.040-0.063 mm was added, and the solvent was removed in vacuo. The residue was slurried with ether, and the solvent was again removed in vacuo to leave a powdery solid.
• IR -CH 3100, 3094, 3068, 3061, 3033, 3017; C-C 1611, 1594, 1573, 1520, 1501; C C/C-N/other 1400, 1382, 1295; 7 CH/other 846, 813, 794, 757, 749.
• IR -CH 3101, 3068, 3030; C-C 1612, 1599, 1576, 1518; C C/C-N/other 1396, 1296; 7CH 818, 759.
• Example 39 2,3-Dihydro-N,N,6-trimethyl-1H-phenalen-2-amine and its maleate salt.
• A Preparation of ethyl (2,3-dihydro-6-methyl-1H-phenalen-2-yl carbonate (U-75,090).
• the extracts were washed with ether and basified with 40%-sodium hydroxide.
• the free base was extracted twice with ether, and the extracts were washed with saturated NaCl and dried (MgSO 4 ) .
• the solvent was removed in vacuo to leave the titled N,N-6-trimethyl-1H-phenalen-2-amine a pink oil (0.18 g, 50%).
• the compound was dissolved in ether, and an ether solution of maleic acid (0.10 g) was added.
• the precipitate was filtered and washed with ether to give a colorless solid (0.24 g; m.p. 268-168.5°C).
• the solution was dried (MgSO 4 ) , and the solvent was removed in vacuo to leave a black oil (5.58 g).
• the compound was dissolved in methylene chloride, silica gel (30 g, 0.040-0.063 mm) was added, and the solvent was removed in vacuo .
• the resulting powder was added to a flash chromatography column that was wetted with 2.5% ethyl acetate/hexane, and the column was eluted with the same.
• the purest fractions were combined to give the sub-titled methylthio compound as a yellow oil (0.64 g) which crystallized on standing.
• the compound was crystallized from ethanol to give a brown solid (0.49 g, m.p.
• Example 41 5 -Hydroxy- 2 -methyl -2,3-dihydro-N,N-di-n-propyl-1H- phenalene-2-amIne, and its hydrobromide.
• the solution was again cooled to -78oC, and a solution of the ester from part (A) above (3.5 g, 0.014 mol) in tetrahydrofuran (80 mls) was added over a period of 15 minutes.
• the mixture was stirred at -78°C for 30 minutes, and the cold bath was removed for 25 minutes.
• the anion solution was again cooled to- 78°C, and methyl iodide (2.6 mls, 2.28 g/ml, 0.41 mol) was added rapidly. After 5 minutes, the mixture was removed from the cold bath, and stirred at room temperature overnight. Ether, saturated NaCl, and water were added, and the layers were separated.
• the urethane from part (E) above (containing some benzyl alcohol, 3.12 g) was combined with acetic acid (80 mls) and 10% palladium on carbon (0.50 g) , and the mixture was hydrogenated in a Parr apparatus using an initial hydrogen pressure of 50 psi for 17 hours.
• the product mixture was filtered through Celite TM , and the catalyst was washed well with ethanol.
• the combined filtrate was evaporated to dryness, and the residue was partitioned between water and 10% sodium hydroxide.
• the aqueous solution was extracted again with ether, and the combined organics were washed .with saturated NaCl and dried (MgSO 4 ) .
• the aqueous solution was extracted again with ether, and the combined organics were washed with saturated NaCl and dried (MgSO 4 ) .
• the solvent was removed in vacuo to leave the sub-titled N,N-di-n-propylamine as a yellow oil (1.25 g, 84%).
• the compound was dissolved in ether, and excess ethereal HCl was added.
• the gummy precipitate was triturated twice with ether and crystallized from methanol/ether to give the sub-titled amine salt as off-white crystals (1.22 g, m.p. 221.5-222.5oC).
• Example 43 2-Hydroxy-2,3-dihydro-2,N-dimethyl-1H-phenalen-2- amine, and its hydrobromide.
• a mixture of the amine hydrochloride from Examples 42, part (B) (0.50 g, 1.80 mmol) and 48% hydrobromic acid (8 mls) was heated in an oil bath maintained at 110-115°C for 12 minutes. The mixture was cooled in ice and diluted in half with water. The crystals were filtered, washed with ether, and dried. The filtrate was evaporated to dryness, and the residue was combined with the crystals. Crystallization from methanol/ether gave the titled 5-hydroxy-2-amine hydrobromide salt as a light purple solid (0.44 g, 79%, m.p. 277- 278°C).
• the endpoints measure dopamine metabolites HVA, DOPAC, and 3MT as a percentage of control (A) or plasma prolactin (B) following 3 mg/kg of chlorpromazine, or 30 mg/kg clozapine or U-64,273A in the Sprague-Dawley rat.
• A dopamine metabolites HVA, DOPAC, and 3MT as a percentage of control (A) or plasma prolactin (B) following 3 mg/kg of chlorpromazine, or 30 mg/kg clozapine or U-64,273A in the Sprague-Dawley rat.
• C Serotonin metabolites as a percentage of control following 1 mg/kg haloperidol, 10 mg/kg of clozapine and 30 mg/kg U-64,273A.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Organic Chemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=25217582

Family Applications (2)

Family Applications After (1)

Country Status (8)

Families Citing this family (5)

Family Cites Families (1)

• 1986
  • 1986-12-15 EP EP87900539A patent/EP0288477A1/en active Pending
  • 1986-12-15 WO PCT/US1986/002698 patent/WO1987004153A1/en not_active Application Discontinuation
  • 1986-12-15 AU AU67770/87A patent/AU588962B2/en not_active Ceased
  • 1986-12-15 JP JP62500313A patent/JPS63502032A/ja active Pending
  • 1986-12-15 EP EP86309767A patent/EP0234113A1/en not_active Withdrawn
  • 1986-12-22 CA CA000525946A patent/CA1321197C/en not_active Expired - Fee Related
• 1987
  • 1987-08-14 KR KR870700731A patent/KR880700667A/ko not_active Application Discontinuation
  • 1987-08-27 NO NO873628A patent/NO873628L/no unknown
  • 1987-08-31 DK DK454987A patent/DK454987A/da not_active Application Discontinuation

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events